Language:

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

The New England journal of medicine, 2019-11, Vol.381 (21), p.1995-2008 [Peer Reviewed Journal]

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1911303 ;PMID: 31535829

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Author: McMurray, John J.V ; Solomon, Scott D ; Inzucchi, Silvio E ; Køber, Lars ; Kosiborod, Mikhail N ; Martinez, Felipe A ; Ponikowski, Piotr ; Sabatine, Marc S ; Anand, Inder S ; Bělohlávek, Jan ; Böhm, Michael ; Chiang, Chern-En ; Chopra, Vijay K ; de Boer, Rudolf A ; Desai, Akshay S ; Diez, Mirta ; Drozdz, Jaroslaw ; Dukát, Andrej ; Ge, Junbo ; Howlett, Jonathan G ; Katova, Tzvetana ; Kitakaze, Masafumi ; Ljungman, Charlotta E.A ; Merkely, Béla ; Nicolau, Jose C ; O’Meara, Eileen ; Petrie, Mark C ; Vinh, Pham N ; Schou, Morten ; Tereshchenko, Sergey ; Verma, Subodh ; Held, Claes ; DeMets, David L ; Docherty, Kieran F ; Jhund, Pardeep S ; Bengtsson, Olof ; Sjöstrand, Mikaela ; Langkilde, Anna-Maria
Subjects: Aged ; Benzhydryl Compounds - adverse effects ; Benzhydryl Compounds - therapeutic use ; Cardiac and Cardiovascular Systems ; Cardiac output ; Cardiovascular Agents - therapeutic use ; Cardiovascular Diseases - mortality ; Clinical outcomes ; Clinical trials ; Combined Modality Therapy ; Congestive heart failure ; Dapagliflozin ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Drug dosages ; Drug therapy ; Drug Therapy, Combination ; Ejection fraction ; Evidence-based medicine ; Female ; Glucosides - adverse effects ; Glucosides - therapeutic use ; Glycated Hemoglobin A - analysis ; Heart failure ; Heart Failure - complications ; Heart Failure - drug therapy ; Hemoglobin ; Hospitalization ; Humans ; Hypoglycemia ; Intravenous administration ; Kaplan-Meier Estimate ; Kardiologi ; Male ; Measurement ; Middle Aged ; Patient outcomes ; Patient safety ; Physiological aspects ; Renal function ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors - adverse effects ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; Stroke Volume - drug effects ; Testing ; Type 2 diabetes ; Ventricular Dysfunction, Left - complications ; Ventricular Dysfunction, Left - drug therapy
Is Part Of: The New England journal of medicine, 2019-11, Vol.381 (21), p.1995-2008
Description: In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and a reduced ejection fraction with or without type 2 diabetes. The risk of worsening heart failure or cardiovascular death was lower among those who received dapagliflozin, regardless of the presence or absence of diabetes.
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
ISSN: 1533-4406
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1911303
PMID: 31535829
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1911303 ;PMID: 31535829

Searching Remote Databases, Please Wait